With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.
A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens.
The researchers note that this finding adds valuable insight for individualized treatment decisions in scenarios where the role of thymectomy is not fully clear.
The systemic review and meta-analysis, believe the researchers, is the first of its kind to characterize the prevalence of depression among these patients.